IP Library Granted Patent US 7,419,803
Granted Patent B2
US 7,419,803 · App. 11/088,472 · Granted Sep 2, 2008

Nucleic acids encoding human coagulation Factor VII polypeptides

Assignee: Novo Nordisk A/S
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,419,803
App. No.
11/088,472
Granted
Sep 2, 2008
Kind
B2
Abstract

The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.

Claims (15)

1. An isolated polynucleotide construct encoding a Factor VII variant polypeptide comprising at least one amino acid substitution selected from the group consisting of amino acids 313, 314, 317-329, 364, 366, 373, and 376 of SEQ ID NO:1, wherein the ratio between the activity of said Factor VII variant polypeptide and the activity of a native Factor VIIa polypeptide is at least 1.25, when the activity is measured in an in vitro hydrolysis assay.

2. The polynucleotide construct as defined in claim 1 , wherein said construct encodes a polypeptide in which S314 is replaced with any other amino acid.

3. The polynucleotide construct as defined in claim 1 , wherein said construct encodes a Factor VII variant polypeptide further comprising at the most 20 additional amino acids in the remaining positions within residues 153-406 of SEQ ID NO:1, each of said residues being replaced with any other amino acid.

4. The polynucleotide construct as defined in claim 3 , wherein said construct encodes a polypeptide in which at least one amino acid corresponding to an amino acid at a position selected from 330-339 of SEQ ID NO:1 has been replaced with any other amino acid.

5. The polynucleotide construct as defined in claim 4 , wherein the additional replacement comprises replacement of one or more amino acids selected from the group consisting of amino acids L305, K157, K337, D334, S336, V158, E296, and M298 of SEQ ID NO:1.

6. The polynucleotide construct as defined in claim 1 , wherein said construct encodes a polypeptide in which S314 has been replaced by an amino acid selected from the group consisting of Gly and Glu.

7. The polynucleotide construct as defined in claim 1 , wherein said S314 has been replaced by Glu.

8. The polynucleotide construct as defined in claim 1 , wherein said polypeptide further comprises replacement of K3 16 by Gln.

9. The polynucleotide construct as defined in claim 1 , wherein the polypeptide is selected from the group consisting of S314E/K316H-FVII and S314E/K316Q-FVII.

10. The polynucleotide as defined in claim 1 , wherein said construct is a vector.

11. An isolated host cell comprising a polynucleotide construct as defined in claim 10 .

12. The host cell as defined in claim 11 , wherein said cell is a eukaryotic cell.

13. The host cell as defined in claim 12 , wherein said cell is of mammalian origin.

14. The host cell as defined in claim 13 , wherein the cell is selected from the group consisting of CHO cells, HEK cells, and BHK cells.

15. A method for producing a Factor VII polypeptide, the method comprising (i) cultivating a cell as defined in claim 11 , in an appropriate growth medium under conditions allowing expression of the polynucleotide construct and (ii) recovering the resulting polypeptide from the culture.

Assignments (1)
CHANGE OF ADDRESS Recorded Jun 19, 2013
From: NOVO NORDISK HEALTHCARE A/G
To: NOVO NORDISK HEALTHCARE AG
Reel/Frame 030653/0189 →
Priority Claims (1)
DK 2001 01627 · Nov 2, 2001 · national
Continuity (3)
Continuation 1028172700 · Oct 28, 2002
Provisional Application 6033538300 · Nov 15, 2001
Related Publication 20060166915A1 · Jul 27, 2006